A Randomized Phase II Trial of Pemetrexed or Pemetrexed/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer

A Randomized Phase II Trial of Pemetrexed or Pemetrexed/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer - A randomized phase II trial of pemetrexed or pemetrexed/bevacizumab in elderly NSCLC patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006912

Enrollment

Registered

2012-02-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous Non-small cell lung cancer

Interventions

pemterexed therapy pemetrexed and bevacizumab combination therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven non-sqamous non-small cell lung cancer 2) Stage IIIB, IV or recullence 3) Measurable lesion(s) 4) age >or= 70 years old 5) Ecog PS 0,1 6) adequate organ function 7) life expectancy > or = 12 weeks 8) Written informed concent

Exclusion criteria

Exclusion criteria: 1)Interstitial pneumonia or pulmonary fibrosis on chest X-ray 2) brain metastasis 3) history of hemoptysis 4) history or complications of obvious diverticulitis 5) cavitary lesions 1cm or more 6) serious complications 7) pleural effusion, ascitis drainage is necessary for, and pericardial effusion 8) active multiple primary cancer 9) pregnancy, lactation, or, intention to pregnancy 10) a history of serious drug hypersensitivity 11) patients whom it is judged to have difficulty in participation in study because of psychosis or neurologic disease 12) The case that is judged to be inadequacy for this study

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
Progression-free survival, Disease-control rate Overall survival Safety	—

Countries

Japan

Contacts

Public ContactTakashi Sone

Hokuriku Thoracic Oncology Group Office

076-265-2273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026